A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2009
At a glance
- Drugs Gefitinib (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 20 May 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 Nov 2005 New trial record.